Raymond James & Associates’s T2 Biosystems, Inc TTOO Stock Holding History

Raymond James & Associates’s Portfolio TTOO Stock Details TTOO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-5	Closed	-$1.03K	–	4097
2022 Q3	$3K	Sell	5 -3	-38%	-$1.97K	﹤0.01%	3911
2022 Q2	$6K	Hold	8	–	–	﹤0.01%	3967
2022 Q1	$21K	Hold	8	–	–	﹤0.01%	4003
2021 Q4	$21K	Buy	8 +1	+14%	+$3.48K	﹤0.01%	4026
2021 Q3	$34K	Hold	7	–	–	﹤0.01%	3953
2021 Q2	$44K	Buy	7 +1	+17%	+$6.46K	﹤0.01%	3925
2021 Q1	$52K	Buy	+6	New	+$63.5K	﹤0.01%	3850
2019 Q3	–	Sell	-9	Closed	-$80K	–	3740
2019 Q2	$80K	Buy	9 +4	+80%	+$46.9K	﹤0.01%	3440
2019 Q1	$65K	Buy	+5	New	+$85.1K	﹤0.01%	3454
2018 Q3	–	Sell	-3	Closed	-$100K	–	3738
2018 Q2	$100K	Buy	+3	New	+$114K	﹤0.01%	3399

Other funds holding TTOO

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James & Associates's TTOO Position: Q4 2022 in Review

Raymond James & Associates sold out of T2 Biosystems, Inc (TTOO) in Q4 2022, closing a stake of 5 shares — an estimated $1.03K sold.

Raymond James & Associates first reported a position in TTOO in Q2 2018 and held it in 10 quarters. The position peaked at $100K in Q2 2018. 20 funds tracked by Wall St. Rank hold TTOO as of Q4 2022.

Raymond James & Associates reported no remaining T2 Biosystems, Inc position as of Q4 2022 after selling out during the quarter.
Raymond James & Associates sold 5 T2 Biosystems, Inc shares in Q4 2022, an estimated $1.03K.
Raymond James & Associates first reported a position in T2 Biosystems, Inc in Q2 2018 and held it in 10 quarters.
Raymond James & Associates's T2 Biosystems, Inc position peaked at $100K in Q2 2018.
20 funds tracked by Wall St. Rank held T2 Biosystems, Inc as of Q4 2022.

Based on Raymond James & Associates's 13F filing for Q4 2022, filed 8 Feb 2023.